Myeloid maturity: ATRA to enhance anti-PD-1?

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Myeloid derived suppressor cells (MDSCs) are associated with resistance to anti-PD-1 therapies. All-trans retinoic acid (ATRA) may induce maturation of MDSCs and alter their immunosuppressive effects. Adding ATRA to pembrolizumab may target this resistance mechanism to enhance the overall impact of anti-PD-1 based immunotherapy.

Keyphrases

induced apoptosis
cell cycle arrest
bone marrow
acute myeloid leukemia
dendritic cells
endoplasmic reticulum stress
signaling pathway
cell death
cell proliferation